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ABSTRACT: Melatonin (ML), a key hormone in chronobiology, is released from 
pineal gland obeying a circadian rhythm, and exerts many of its actions through MT1 
and MT2 receptors. The circadian clock, in face of nowadays demands of irregular 
schedules and technologies pressure, is forced to misalignment, a consequence related 
with different chronic diseases, as obesity and type 2 diabetes mellitus (T2DM). On the 
other hand, sleep disorders, featured by circadian disorders, can result from diabetic 
conditions. We review data showing that disturbed circadian rhythms may result in 
glucose intolerance, T2DM and other metabolic disorders. Here, we praise melatonin as 
a link between chronodisruption and diabetes and a potential adjuvant for its treatment. 
We first describe melatonin physiological role on circadian system, the involvement of 
chronodisruption factors in diabetes pathogenesis, to later focus on the beneficial role of 
melatonin in this condition. Lastly, we summarize current knowledge about the 
therapeutic properties of melatonin in diabetes.  
 
 
INTRODUCTION  
 
Isolated by Aaron Lerner in 1958 from bovine pineal glands (1), Melatonin 
(ML), an indoleamine with the chemical name 5-methoxy-N-acetyltryptamine (2), is 
discharged from epiphysis or pineal gland in a pulsatile manner, in consonance with 
light-dark cycle and daily and seasonal changes (3). ML shows a circadian rhythm 
controlled by circadian pacemaker cells, the “master circadian clock” on 
suprachiasmatic nucleus (SCN), situated in the ventral part of the hypothalamus (4). In 
mammals, its high levels in plasma during night was found to be 80-100 pg/mL and low 
levels during day of 10-20 pg/mL (5). ML plasma hormone profile reproduces exactly 
pineal activity, since ML is not stored in the pineal gland (5). It is also released by other 
organs or cells, but in less amount or due to a specific stimulis (6). 
ML synthesis occurs according the following steps: tryptophan (Trp), the 
synthetic precursor, is metabolized into 5-hydroxy-Trp (5-HTP) by Trp-hydroxylase 
(TPOH), which is then converted into 5-HT by an aromatic amino acid decarboxylase 
(AAAD). 5-HT is first acetylated by arylalkylamine-N-acetyltransferase (AA-NAT) 
into N-acetylserotonin (NAS), and finally O-methylated by HIOMT to produce ML (5). 
 
ML, mostly released from pineal gland during night, activate MT1 and MT2 
receptors by a feedback mechanism on SCN, leading to a phase shift in local and 
biologic circadian rhythms (3). In fact, ML is a key molecule in chronobiology and is 
the most important efferent hormonal signal acting as an internal “zeitgeber” (7), either 
by resetting feedback signal to SCN or by timing other cells in central nervous system 
(CNS) and peripherally (6). Thus, ML indicates the time of the day to peripheral organs 
and tissues (7), regulating the rhythmicity expression of “clock genes” at a cellular level 
(8) in order to adjust their metabolic activity (7) (Figure 1). ML also has specific actions 
in sleep induction, vasomotor regulation and adrenal activity, along with anti-excitatory 
actions, anti-inflammatory properties, antioxidant actions and energy metabolism 
modulation (6). 
Human clock is able to maintain 24-h rhythms, even in the absence of any 
environmental cues. However, it uses these environmental signals to synchronize their 
endogenous rhythms, called “zeitgeber”, meaning time givers, of which the most 
important neuronal signal is light (9). In mammals, after light detection by retinal 
photoreceptors, action potentials are transferred to the SCN via the retinohypothalamic 
tract (10). The paraventricular nucleus of the hypothalamus projects to the preganglionic 
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neurons at the intermediolateral column of the upper thoracic cord. After synapsing with 
these cells, the preganglionic axons go on to the rostral third of the superior cervical 
ganglia, sending postganglionic sympathetic projections to pinealocytes, the endocrine 
elements of the pineal gland (10). During darkness, the SCN sends neural impulses 
which induce norepinephrine discharge from the postganglionic terminals near the 
pinealocytes, leading to the nightly rise in pineal melatonin synthesis (11). These 
neurological connections occur in a different way when light is present during night, 
suppressing ML production and declining its circulating levels (12) which can 
negatively impair metabolic functions (13). Additional “zeitgebers” as feeding, physical 
activities, social environment and biological stress also contribute to modulate circadian 
rhythm (14-16). Simultaneously, the master circadian clock integrates information from 
epigenetic factors and synchronizes oscillators on peripheral tissues by controlling 
about 10-20% of cellular genes (16).  
 
Therefore, mammalian cell-autonomous molecular clock is generated in 24 –
hour rhythm by multiples interlocking molecular loops located in almost every cell, 
involving rhythmic transcription of specific “clock genes” and interactions of the 
encoded proteins, organized hierarchically by the “master clock” (17, 18).   In the last 
decade, the clock mechanism was first described as a simple transcription‐translation 
feedback loop (TTFL) driven by four integral clock proteins and including a positive 
and a negative limb.  In this way, BMAL1 (brain and muscle ARNT-like 1) and 
CLOCK (circadian locomotor output cycles kaput), components of the positive limb, 
dimerize and bind to E-box-containing DNA elements and, consequently, activate the 
transcription of cryptochrome (CRY1 and CRY2) and period genes (PER1 and PER2). 
CRY and PER are repressors genes, that belong to the negative limb, inhibit the 
function of CLOCK/BMAL1 (17, 18). PER and CRY complexes are degraded through  
E3 ubiquitin ligase pathways, reliving the repression of CLOCK/BMAL1, and a new 
~24h cycle begins (18, 19). Along with this loop,  casein kinases, CKIε and CKIδ,  
regulated by phosphatases, PP1 and PP5, control the  activity of Per/Cry complexes 
(18). 
 
After this time, multi-loop oscillators have been introduced by discovering 
additional clock genes. These included a second TTFL activated by retinoid-related 
orphan receptors (RORα, RORβ and RORγ) and repressed by REV–ERBα (encoded by 
NR1D1) and REV–ERBβ (encoded by NR1D2) (18, 19). Another interlocking 
transcriptional feedback loop involves the  PAR-bZip (proline and acidic amino acid-
rich basic leucine zipper) transcription factor family, including DBP (D-box binding 
protein), TEF (thyrotroph embryonic factor) and HLF (hepatic leukaemia factor) (19). 
 
These molecular feedback loops, expressed in  multiple tissues in the body,  are 
able to coordinate  rhythmic processes in each cell (20). However, clock genes 
polymorphisms variants may lead to metabolic disorders as dyslipidemia, diabetes, food 
intake and gestational diabetes (21). Likewise, inappropriate cues may result in central 
clock misalignment and consequently cellular clock genes machinery malfunctioning, 
leading to circadian disruption (chronodisruption) (11)  and metabolic conditions as 
diabetes and obesity (22).  
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MELATONIN RECEPTORS 
 
Melatonin is released both from pineal gland and retina and many of its actions 
are mediated through interaction with two high-affinity G protein-coupled receptors (3). 
Melatonin receptor 1 (MT1) and melatonin receptor 2 (MT2) are the main two types 
melatonin receptors, both typically coupled to Gi/o- type proteins (23). These receptors 
show distinct chromosomal sites, MT1 with 4q35.1 for MTNR1A gene and MT2 with 
11q21-q22 for MTNR1B gene (23). The MT1 melatonin receptors couple to both 
pertussis toxin (PTX) sensitive Gi and insensitive Gq/11 G proteins. Binding to these 
receptors results in a decrease of forskolin-stimulated cAMP formation and inhibition of 
both protein kinase A activity and phosphorylation of the cAMP responsive element-
binding protein (CREB). Additionally, ML, through MT1, can potentiate conductance 
of inward-rectifier potassium channels (Kir), stimulate phosphorylation of mitogen-
activated protein kinase 1/2 (MEK1/2) and extracellular signal-regulated kinase 1/2 
(ERK1/2).  Regarding MT2 melatonin receptor signaling, its activation inhibits 
forskolin-stimulated cAMP and cGMP formation. In the SCN, MT2 melatonin receptors 
activate protein kinase C (PKC), while in retina reduce neurotransmitter release through 
calcium-dependent mechanisms (24). 
A high degree of sequence homology is shared by MT1 and MT2 receptors (23). 
Melatonin bind to both MT1 and MT2 receptors with high affinity being methoxy group 
and acetamide side chain responsible for, respectively, ML intrinsic activity and binding 
affinity in humans (23). Curiously, there are simultaneously additive, synergistic, or 
opposing responses when activation of both MT1 and MT2 melatonin receptors in the 
same or in different cells (3). In fact, human MT1 and MT2 receptors can form homo- 
and hetero-oligomers between themselves and other G protein–coupled receptors, 
considering that MT1/MT2 heterodimers formation is 3- to 4-fold lower than the 
formation of MT1/MT1 homodimers and is similar to the formation of MT2/MT2 
homodimers (25). ML receptor heteroligomers have an essential role in retinal function, 
once MT1/MT2 heterodimers in mouse rod photoreceptors modulate light sensitivity 
via a phospholipase C (PLC)/PKC pathway, which is not normally triggered by 
activation of monomeric units (26). MT1 and MT2 receptors are also able to 
heterodimerize with the serotonin receptor (5-HT2C) (36), which is particular relevant 
concerning agomelatine, a ML receptor agonist that exerts antidepressive effects by 5-
HT2C receptor antagonism (27).  
ML can also bind to a third ML receptor, previously defined as MT3, a member 
of the quinone reductases family (23). Additionally, ML also exerts indirectly its effects 
through nuclear  receptors, binding to a retinoid-related orphan nuclear hormone 
receptor from the RZR/RORα family, a member of transcription factors (28) and 
through direct interactions with intracellular proteins, including calmodulin, calreticulin 
and tubulin (29). The highest expression of ML receptors has been found in the pars 
tuberalis of the anterior pituitary (30), and also in   quite  a number of sites in the CNS 
(31). Likewise, more membrane receptors have been found in peripheral organs, such as 
in gastrointestinal tract, in gallbladder epithelium, parotid gland, exocrine and β-cells of 
endocrine pancreas, skin, breast, uterus, fetal kidney, cardiac ventricular wall, central 
and peripheral vasculature aorta, brown and white adipose tissues, platelets, immune 
cells, cancer cell lines (6).  
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WHEN ARTIFICAL LIGHT CHANGES OUR NATURAL PATTERNS 
 
A wide diversity of physiological and behavioral circadian rhythms are 
controlled by internal biological clocks, predominantly synchronized by the 
environmental light/dark cycle (12). In face of social and economic demands in 
industrialized countries, people became trapped in some type of permanent night and 
rotating shift work, and also susceptible to “jet lag” due to travels across several time 
zones (32). Consequently, these type of works mean irregular schedules and forced 
exposure to nocturnal lighting, showing significant disruptions in sleep architecture and 
other markers of circadian synchronization (33). Sleep disruption is also a core feature 
of posttraumatic stress disorder resulting in circadian disruption (34). A “social jet 
lag” also has been linked to circadian misalignment, due to changes in sleep behavior, 
as shorter sleep duration and later chronotype (35). Simultaneously, there was a rise of 
exposure to light during night related with increased time of wakefulness, use of 
artificial light, television, computer monitors and other technologies (29) that disrupt 
the natural cycle of sleep/wakefulness, exposing human organism to light at atypical 
biologic times (32). Curiously, nocturnal blue light exposure presently growing due to 
the proliferation of energy-efficient lighting (LEDs) and electronic devices appears to 
induce the strongest ML inhibition and cause more disturbances in clock balance at 
night. It was also suggested that development of lighting systems maintaining the 
natural ML rhythm could decrease these effects (36). Caffeine (37) and alcohol (38) 
might also contribute to cause phase shift in circadian pacemaker time.  
 
 
CONSEQUENCES OF CHRONODISRUPTION 
 
 Artificial light during night has negative chronobiologic effects (32), 
suppressing ML synthesis and secretion in different species, including humans (12). 
Accordingly, alterations in ML production result in an imbalance of biological rhythms, 
converging to marked misalignment of the central circadian pacemaker. Consequently, 
the result is the disorganization of peripheral cellular clocks and malfunctioning at 
tissue, molecular and cellular levels (32) (Figure 2).  
Circadian disruption reflects a desynchronization either among endogenous 
circadian (~24-hour) rhythms or between them and the environment with consequences 
to cardiometabolic health (39). Considering ML essential to optimize energy balance 
and metabolism, there is increasing evidence that disruption of normal circadian 
rhythms may lead to metabolic circadian disorders, namely glucose intolerance, insulin 
resistance and obesity (22) as also metabolic syndrome (40, 41). Light-dark 
misalignment might be able to accelerate weight gain, in both animals and humans, not 
only due to changes in ML patterns, but also in eating behavior, hormones and in 
response to stress (42). However, obesity and other metabolic diseases might be able to 
disturb normal clock timing and amplitude in multiple organ systems, and consequently 
exacerbate disease progression (43). Therefore, other lipid metabolic conditions have 
been related to chronodisruption (44). On a cardiovascular view, shift work was 
associated with an increased risk of coronary disease, acute myocardial infarctions and 
cerebrovascular accidents, even after adjusting for possible confounds (45). Circadian 
misalignment is also a factor to increase the risk of developing cancer, particularly 
breast (46), colon (47) and prostate cancer (48).  
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DIABETES – AN EMERGENT PROBLEM LINKED TO CIRCADIAN 
MISALIGNMENT 
 
Diabetes is becoming a global problem, affecting around 387 million people 
worldwide, 90% with type 2 diabetes, and with an expectable double increase in 
prevalence over the next 20 years (49). This prevalence increase is related with 
nowadays lifestyle, featuring by excessive food consumption, sedentary life style and 
lack of physical activity (49), ultimately leading to glucose homeostasis disruption (50). 
In addition to pancreatic β-cell dysfunction, insulin resistance, abnormal adipogenesis 
and gluconeogenesis increase play an important role in T2DM progression (49). 
However, disruption of circadian rhythm mechanisms and genetic susceptibility has also 
been implicated in the development of T2DM (51). Circadian misalignment also reflects 
itself in timing disruption of food intake and biological functions, sleep disorders, 
changes in ML signaling pathways and clock gene expression and presence of 
polymorphisms. Altogether, these consequences have also been attributed to diabetes 
pathogenesis (51). 
 
Although people with primary sleep disorders have been strongly associated 
with increased T2DM, diabetes may also lead to disruption in sleep quality, as a result 
of thirst at night, nocturia, polyuria, diabetic neuropathy and associated pain, symptoms 
of hypoglycemia, and also due to  associated chronic illness as obstructive sleep apnea, 
hypertension and cardiovascular complications, cerebrovascular accidents and 
depression (52). 
 Epidemiologic studies have shown an association between shift work and risk 
of developing TDM2, while ML supplements have been used to treat insomnia or jet lag 
(53). Additionally, evening light exposure, associated with changes in timing and 
amount of ML secretion, expression of clock genes and food intake, is suggested to be 
more correlated with diabetes risk than light exposure in other periods of time, though 
these consequences were proposed to be independent of changes in nocturnal ML levels 
(54). 
 
 
MELATONIN RECEPTORS AND DIABETES 
 
ML can influence either directly clock machinery in pancreas or indirectly via 
the SCN (55).  Molecular and immunocytochemical studies confirmed the existence of 
MT1 and MT2 receptors in Langerhans islets  and in human pancreatic tissue, in which 
ML could exert its effects to maintain circadian rhythms and consequently glucose 
homeostasis (55). The possible association between ML receptors and T2DM 
pathogenesis has been investigated using ML receptor knockout (KO) mice to 
determine the mechanisms by which these receptors could contribute to the regulation 
of glucose homeostasis and insulin sensitivity. MT1 receptor silencing showed higher 
mean blood glucose levels comparing to controls (56), as well as significantly impaired 
glucose metabolism  and insulin resistance comparing with wild type (WT) and MT2-/- 
mice (57). Moreover, MT1 -/- and MT2 -/- mice abolished the daily rhythm in blood 
glucose levels (58). Pinealectomy in rats, by abolishing endogenous ML levels, altered 
the daily rhythm in blood glucose levels with higher levels during the night (59).  
Additional growing evidence has shown a clinical relationship between ML 
receptors variants and impaired insulin secretion, ineffective glucose metabolism (60, 
61), increased risk of T2DM (62) and gestational diabetes mellitus (63). Several large 
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genome-wide association studies have identified more than 150 risk alleles for T2DM, 
most of them affecting genes that encode intracellular proteins mediating insulin 
secretion by β-cells or transducing the effects of insulin in target tissues, responsible to 
increase individual susceptibility to diabetes (53). In this context, common single 
nucleotides polymorphisms (SNP), as rs1387153 and rs10830963, were identified 
located near the gene MTNR1B that encodes the MT2 receptor of ML (62). Among 
these SNP, those causing loss of ML receptor function were associated with the highest 
incidence of T2DM. The SNP rs10830963, the variant with the strongest association 
signal, was related to impairment of early insulin secretion and β-cell dysfunction, 
which might be responsible for increasing the T2DM risk (62). 
 ML during the night is released from pineal gland and binds to MT2 receptors, 
leading to a reduction of ATP conversion to cyclic AMP (cAMP) and consequently 
reduction of protein kinase A activation. This pathway ultimately results in the 
inhibition of insulin secretion in response to glucose metabolism. However, when MT2 
receptor variants  associated with diabetes risk are present, MT2 receptors are up-
regulated in islet β-cells leading to a higher inhibition of cAMP  formation and 
consequently a stronger inhibition of glucose-stimulated insulin secretion (53). 
 
 
GLUCOSE HOMEOSTASIS AND MELATONIN 
 
Growing evidence of an interplay between ML and diabetes have been 
increasing (64), supporting that loss of nocturnal ML secretion is associated with a 
higher risk of developing T2DM (65). In fact, pinealectomy and sympathetic 
denervation of the upper sympathetic ganglia lead to a reduction in ML secretion, and, 
on the other hand, increased food consumption and weight gain (66). Removal of the 
endogenous source of ML in rats was also associated with a lower insulin response, 
with glucose intolerance and a decrease in Glut4 expression in both adipose and muscle 
tissues (67). Furthermore, it also decreased hepatic and muscular glycogenesis and 
caused an increase in blood pyruvate concentrations (66).   
At a cellular level, ML treatment also showed improvements in glucose 
homeostasis by stimulating glucose transport in skeletal muscle via phosphorylation and 
activation of insulin receptor substrate 1 (IRS-1) and phosphotidyl-inosytol 3 kinase 
(PI-3K), and hence restoring the vascular actions of insulin and stimulating glycogen 
synthesis in hepatic cells, respectively (68). In vitro studies with human pancreatic islet 
cells suggested that ML has direct stimulatory effects in β-cells by increasing insulin 
secretion and improving glucose sensitivity (69, 70). Furthermore, persistent activation 
of ML signaling in vitro had the potential to attenuate β-cell loss and dysfunction 
associated with molecular stress present in T2DM (71). This observation was explained 
by an activation of the cAMP-dependent signal transduction pathway and decrease of 
toxicity β-cell apoptosis due to a reduction of caspase-3 cleavage, decrease on stress-
activated protein kinase/Jun-amino-terminal kinase activation and attenuation on 
oxidative stress response (71). 
Evidences of ML regulation in human metabolic balance have been emerging. A 
hypothetical antagonism interplay between insulin and ML was evident in a cross-
sectional study enrolling 1,075 women without diabetes, hypertension, or malignancy, 
that found that higher nocturnal ML secretion was independently and inversely 
associated with insulin levels and insulin resistance (72).  A case-control study among 
women participating in the Nurses’ Health study found an association between ML 
secretion and risk of developing T2DM, independently of  established diabetes risk 
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factors,  and that non-diabetic individuals with low ML secretion during night showed 
an increased risk of developing diabetes (65). Another study showed that nighttime ML 
level was significantly lower among subjects with proliferative diabetic retinopathy, 
compared with healthy subjects, a finding suggested to be due to advanced dysfunction 
of retinal light perception, and consequently ML secretion alterations (73).   
 
 
 
MELATONIN AND INSULIN 
 
Insulin secretion, similarly to ML, shows a circadian pattern in humans, 
revealing an increase from a low point between midnight and 6 AM and reaching a peak 
between noon and 6 PM (74).  A functional antagonism between insulin and ML might 
exist as at night insulin levels are low and ML levels elevated, whereas during the day 
insulin levels are high and ML low (75). ML improves insulin signalization both in 
CNS and peripheral tissues, and insulin potentiate an elevation of ML secretion at night 
(64). The circadian clock is able to induce variations in insulin sensitivity in T2DM 
patients (51), that present lower circulating levels of ML, comparing to healthy 
individuals (76). Pineal ML synthesis has been reported to be decreased in type 2 
diabetic Goto-Kakizaki (GK) rats, compared with non-diabetic Wistar rats (77), and 
local hyperglycemia can be involved in this pathogenesis (64). These differences in 
diabetic rats were attributed to a different expression pattern of ML synthesizing 
enzymes, less amount of its precursors, and less noradrenaline levels in pineal glands 
(77). Attending to the role of catecholamines in decreasing insulin secretion and 
stimulating ML synthesis, it was observed that noradrenaline, adrenaline and ML levels 
were reduced in type 2 diabetic GK rats, that are characterized by high insulin levels 
(78). Further, decreased pineal gland size and up-regulation of inhibitory β-
adrenoceptors (71) were observed in animal models of T2DM. 
MT1 and MT2 receptors, involved in insulin secretion modulation, are both 
expressed in Langerhans islet (55) and their desynchronization signaling pathways may 
be involved in diabetes pathogenesis. ML influences insulin secretion by MT1 and 
MT2-receptor-mediated effects (69). There are divergence results on receptor function, 
since some authors observed an increase in insulin secretion from isolated human islets 
mediated by ML (70), while others reported a reduction of insulin secretion in rodents 
islets (69, 79, 80).  In isolated pancreatic islets of neonate rats and INS-1 cells, ML 
induced insulin secretion through forskolin-stimulated cAMP production, an activator 
of adenylate cyclase (AC) activity  (69, 79, 80). According, luzindole, a competitive ML 
receptor antagonist, is able to mostly reverse this inhibitory effect of 
adenylcyclase/Camp on insulin production (79). These findings indicate the potential 
inhibitory influence of ML on pancreatic β-cells by cAMP-signaling pathway via MT1 
receptors. ML actions extend to other molecular mechanisms as the inhibition of cyclic 
guanosine 3',5'-monophosphate (cGMP) signaling pathway mediated by MT2 receptor 
consequently suppress insulin secretion (81). The circadian clock genes probably are 
modulated by cGMP, via protein kinase G (PKG), leading to a phase shift and resetting 
of secretion rhythms (55).  In INS-1 cell line, ML seemed also to have a dose-dependent 
stimulation of 1,4,5-triphophate (IP3) increasing effect, resulting in insulin release 
mediated by intracellular calcium mobilization (82).  
Furthermore, ML arises as an important hormone to improve β-cell survival, 
attenuation of β-cell turnover and β-cell function enhancement (83). This regulation can 
be explained by the cAMP-dependent signal transduction pathway involving PKA, 
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essential for the stimulation of acute insulin response to glucose, and CREB activation, 
critical to maintain adequate β-cell mass, function and protection against B-cell 
apoptosis (71).  
 
 
CHRONODIRUPTION AND DIABETES 
 
Several lines of evidence have correlated circadian disruption and impairment of 
glucose balance (Figure 3). A human experimental study evaluated the adverse 
cardiometabolic implications of circadian misalignment, as occurs acutely with jet lag 
and chronically with shift work, showing systematic increases in postprandial glucose, 
insulin and mean arterial pressure (84). Shift workers, under the circumstances of 
irregular sleep schedules and sleep deprivation, show an increased risk of diabetes 
relatively to day workers (85), though not achieving statistical significance. By other 
side, patients with diabetes presented sleep disorders and rhythmic disturbances (86). 
Additionally, as occur in shift work, induced sleep restriction showed a significant 
decrease in insulin sensitivity and an increase in low-grade inflammation (87), known to 
have a potential role in diabetes, obesity and metabolic disorders (88). Short sleep 
duration, sleep quality and long sleep duration have been connected to an increasing risk 
of developing T2DM (89). Men reporting ≤5 and 6 h of sleep per night were twice as 
likely to develop diabetes, as those who reported sleeping 7 hours per night. Long sleep 
duration also increased the risk of developing diabetes (90). Similarly, healthy adults 
exposed to prolonged sleep restriction, with concurrent circadian disruption, had 
significantly decreased resting metabolic rate and increased postprandial plasma 
glucose, via inadequate pancreatic β-cell responsivity (91). Circadian misalignment 
experimentally induced in healthy subjects showed a decrease in leptin concentrations 
(84). Leptin, synthetized by adipocytes, inhibits food intake and influence peripheral 
metabolism of glucose and lipids (92).  Since reduced levels of leptin can stimulate 
appetite and distort energy expenditure (84), it may provide a mechanism underlying the 
increased risk for obesity and diabetes. In addition, circadian misalignment resulted in a 
complete inversion of cortisol profile that similarly can be associated with insulin 
resistance and hyperglycemia (84). As cortisol is an important regulator of peripheral 
clocks, cortisol rhythm desynchronization may have an impact on metabolic 
homeostasis (92). Furthermore, glucose intolerance is associated with high circulating 
cortisol concentrations, which is responsible for raising blood glucose levels through 
different mechanisms (93). 
 Glucagon also has an important role in blood glucose homeostasis, and total sleep loss 
was shown to lead to a decrease in glucagon levels in humans (94).  
 
These data are in concordance with results obtained from animal studies. 
Disturbance of circadian rhythms due to shift work, sleep loss, or nocturnal lifestyle 
were simulated by experimental circadian rhythms disruption in diabetes-prone HIP 
rats, showing a rapid manifestation of T2DM, due to accelerated loss of β-cell function 
and mass attributed to the increase of β-cell apoptosis (95). A recent study showed that 
combination of ML and metformin in rats concomitantly exposed to circadian 
disruption and diet-induced obesity, synergistically change the progression of metabolic 
dysfunction through improvement of adiposity, circadian activity, insulin sensitivity and 
islet cell failure (83). 
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CHRONODISRUPTION AND OBESITY – IMPLICATIONS IN T2DM  
 
 Chronodisruption and reduction in sleep duration over the last decades are 
conditions involved in obesity increase (96, 97).  In turn, overweight and obesity are 
main risk factors for T2DM pathogenesis  (98). Here we review some data of circadian 
disruption and its consequences in obesity, a mechanism that can be involved in 
diabetes pathogenesis. Disruption in central clock can decrease energy expenditure and 
consequently lead to obesity induction (99). Moreover, exposure to light at abnormal 
hours was associated with weight gain in rodents and with higher odds ratio for obesity 
in humans (14, 100). Brown adipose tissue (BAT) is positively related with a protective 
role in diabetes and lower glycaemia in humans (101). Prolonged light hours exposure 
lead to an increase in body fat mass through reduction of BAT activity and to a 
reduction of sympathetic stimulation of BAT and the β3-adrenergic intracellular signal, 
which consequently reduced the uptake of fatty acids from triglyceride-rich proteins and 
of glucose by BAT (99). Adipose tissue secretes molecules that modulate food intake, 
metabolic activity and fat deposition. Consequently, disturbances in these functions, 
could lead to metabolic dysregulation, influencing the timing of food intake and fat 
deposition (97). Moreover, some genes in adipocytes exhibit circadian rhythms and 
disturbances in central or peripheral circadian clock can have impact on normal 
functioning of adipocyte genetic machinery (97). Circadian clock gene network 
perturbations play an important role in metabolic balance dysregulation, leading to 
alterations of food intake rhythm, hyperphagia, hyperlipidemia and hepatic steatosis 
(102). Deficiency of ML, observed in sleep deprivation, has been demonstrated to be 
correlated with obesity (96), and ML supplementation might have beneficial effects on 
obesity and its complications (103). Furthermore, BAT was suggested to be a potential 
target for novel anti-obesity drug development, seeming to be a factor whereby animals 
lose weight in response to ML administration (36). Additionally, leptin and adiponectin, 
adipokines with an important role in glucose and lipid homeostasis, can have their 
circadian rhythms altered in obesity, and ML has been found to normalize the 
expression and secretion patterns of both adipokines (29). 
Further studies have shown disruption of the circadian clock, either via dietary 
restriction or phase shifting, could affect rhythms within the gut microbiome 
constituents (104). Recently, it was suggested that human microbiome may affect the 
risk of obesity and T2DM, and that modulation of microbiome might reduce that risk 
(105). As ML, present at high levels in the gut, could have a plausible impact on this 
balance (104), we hypothesize whereas this hormone could play a plausible beneficial 
impact on this homeostasis. 
 
 
 
OXIDATIVE STRESS DELETERIOUS EFFECTS ON DIABETES  
 
Hyperglycemia causes a reduction in the levels of protective endogenous 
antioxidants and increases generation of free radicals, related with β-cell function 
impairment (106). Oxidative stress, one of the most harmful outcomes related to 
diabetes (64), may significantly decrease insulin cell signaling and glucose uptake by 
adipocytes (107), and attenuation of ML synthesis may aggravate this situation. 
Consequently, it could result in mitochondrial dysfunction and in cellular deleterious 
effects, which can be prejudicial for pancreas homeostasis, as pancreatic β-cells are 
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particularly susceptible to oxidative stress due to its low-antioxidative capacity (107). 
Additionally, ML parenteric administration was able to reduce the degree of 
lipoperoxidation and protein glycosylation (108). In vivo and in vitro studies showed 
ML attenuate oxidative stress in T2DM (13). In nondiabetic and T2DM human 
pancreatic islets, ML administration, mimicking a typical nightly exposure, showed 
attenuation of proteotoxicity-induced β-cell apoptosis evidenced by reduced caspase-3 
cleavage, decreased activation of stress-activated protein kinase/Jun-amino-terminal 
kinase and diminished oxidative stress response (71). In T2DM non-insulin dependent, 
it was found, after 30-day ML supplementation, an improvement of antioxidative 
defense, suggesting ML supplementation as a beneficial additional treatment for 
controlling diabetic complications, especially considering the link between oxidative 
stress, aging, and diabetes type 2 (109).  
Diabetic retinopathy is considered a major complication of T2DM, mainly due 
to the adverse effects of oxidative stress and inflammation (110). ML could protect 
against diabetic retinopathy, reducing some retinal histopathological changes in diabetic 
rats (111), by stimulation Akt-Nrf2-mediated antioxidant system and simultaneously 
inhibition NF-κB and its downstream proinflammatory cytokine production (112). Its 
protective functions were also mediated by reduced elevated VEGF expression, 
allowing reversion of retinal dysfunction due to DM (112).  
Another complication of diabetes is neuropathy, with a prevalence rate of 50-
60%, a condition in which ML also showed neuroprotective effects, mostly by 
attenuating NF-κB activation cascade and oxidative stress (113). Previous studies added 
to these evidences other protective roles of ML in renal, corneal and neural DM injuries 
(113-115).  
 
Additionally, antioxidant properties of ML showed to be able to improve 
impaired functions of hepatic mitochondria in diabetic obese animals, thought to play a 
role in obesity and T2DM, in terms of development of liver steatosis and insulin 
resistance (116). In diabetic rats, ML also has the capacity to inhibit lipid peroxidation 
and regulate antioxidant enzymes, for which contribute its anti-apoptotic effects and 
antioxidant properties (117). The protection exerted by ML is mediated by directly 
scavenging free radicals (118) and stimulating the activity and expression of antioxidant 
enzymes, through the metabolization of free radicals and radical products to innocuous 
metabolites (119). The antioxidant effects of ML seem to rely on MT receptor-
dependent and -independent mechanisms. ML binds to the MT3 binding site and to the 
cytosolic enzyme quinone reductase 2 (QR2), which in turn acts as a detoxifying 
enzyme to increase antioxidant defense (23). ML exhibits several unique features which 
differ from the classic antioxidants. In fact, ML and its metabolites are able to neutralize 
numerous toxic oxygen derivatives radicals (120). ML has the capacity to scavenge up 
to 10 reactive oxygen species (ROS) versus the classic antioxidants, being superior to 
vitamin C and vitamin E, under in vitro and in vivo conditions (120). So, ML has the 
ability to scavenge free radicals, known as the free radical scavenging cascade, but also 
to be induced under moderate oxidative stress (120).  
Moreover, its antioxidative effects are potentiated by its capacity to activate 
cytoprotective enzymes, such as superoxide dismutase, catalase and glutathione 
peroxidase, involved in metabolization of free radicals and radical products to 
innocuous metabolites  (119). A further hypothesis was investigated concerning the fact 
that ML might influence receptor-mediated function by changing redox state at cellular 
level (23).  
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MELATONIN – IS IT AN OPTION TREATMENT?  
 
Suppression of ML synthesis and secretion during night by nocturnal light 
abnormal exposure could be a critical factor for T2DM (121). As disturbed circadian 
rhythm, may be related to the T2DM pathogenesis, ML might be a useful option due to 
its ability to return both phase and amplitude of circadian clock (51). Chronic 
oral ML treatment showed reduction of liver steatosis and mitochondrial dysfunction, 
both enrolled in the development of insulin resistance in diabetic obese rats (122).  It 
also decreased plasma glucose and hyperlipidemia levels (123) in obese rats, and 
showed a protective effect against the onset of diabetes (123). An increase in insulin 
secretion and a decrease in sensitivity of peripheral tissues and of pancreatic islet β-cells 
to insulin,  a common pattern in aging, were counteracted with chronic ML in a murine 
model of accelerated aging (124). A long-term ML administration in Zucker diabetic 
fatty rats, as these beneficial effects on insulin sensitivity, have also been linked to body 
weight reduction and improved lipid metabolism (125). In male Wistar rats fed a high 
fructose diet, two weeks of ML administration also reduced insulin resistance and 
showed an increase in serum adiponectin levels and a reduction in leptin levels (126). 
Moreover, levels of circulating free fatty acids (FFA) and serum tumor necrosis factor 
(TNF-α), important factors implicated in the development of insulin resistance and 
diabetes type 2 (127), have also been reduced by ML treatment in rats (126). A study 
involving ZDF rats showed that ML administration during six weeks increased Ca
2+
 
levels in liver, pancreas, muscle and in different adipose tissues (128), a probable 
mechanism of action of ML antidiabetic effects. This effect was explained by the way 
that increase in Ca
2+
 levels appears to improve insulin sensitivity, which may in turn be 
related to the elevation of adiponectin levels after ML administration (128). A recent 
study, using a metabolic syndrome rat model, showed that treatment with both low- and 
high- ramelteon doses attenuated cardiac injury and improved insulin signaling in white 
adipose tissue (129).  
 
Evidences in humans have been providing ML treatment beneﬁcial effects on 
T2DM patients, as well as on other related conditions. A placebo-controlled double-
blind study, including 46 type 2 diabetic patients, reported that combination of zinc 
acetate and ML improved dyslipidemia and decreased the level of microalbuminuria 
(130). Other study using the same combination, both in monotherapy or together with 
metformin, showed improvement in glycemic control in T2DM (131). In insomnia 
patients with diabetes prolonged-release ML treatment during 5 months showed 
beneficial effects on glycated hemoglobin (HbA1c) (132). Additionally, administration 
of ramelteon to T2DM patients for 3 or 6 months did not change the level of HbA1c, 
however its discontinuation slightly increased the HbA1c level from 6.7% to 6.9% 
(133). Another study of isolated human islets from both healthy and T2DM donors had 
extended the evidence of ML crucial role in preservation of β-cell mass and function in 
T2DM patients, and revealed that in islets exposed to chronic hyperglycemia, ML could 
restore glucose-stimulated insulin secretion (71).  
Melatonin [Circadin®] and other analogues, non-selective MT1/MT2 receptor 
ligands, are presently used in therapeutically conditions. For instance, ramelteon 
[Rozerem®] in insomnia, agomelatine [Valdoxan®] in depression and tasimelteon 
[Rozerem®] in non-24-h sleep-wake disorder (3). Melatonin and related analogues also 
find therapeutic actions in jet lag, shift work and others circadian disorders, depressive 
disorders, dementia and neurologic diseases, as well as in breast and prostate cancers (3) 
Non-selective MT receptor agonists also include 6-chloromelatonin, 6-
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hydroxymelatonin, 2-iodomelatonin, GR 196429, UCM 793 and 2-methoxy-α,β-
didehydro-agomelatine (23).  
Melatonin treatment in humans showed a strong safety profile and only mild 
adverse effects, such as headache, dizziness, nausea and sleepiness, without any serious 
adverse effect both with short or long-term use (134).  
Despite these evidences in favor of melatonin, a recent placebo-controlled 
single-blind study including 21 healthy women reported that 5 mg of melatonin 
decreased glucose tolerance, both in the morning and evening, by decreasing insulin 
release and insulin sensitivity, respectively. (135).  Furthermore, a common genetic 
variant associated with increased T2DM risk, MTNR1B rs10830963, was related with 
worst glucose tolerance in response to melatonin administration (136). More studies are 
needed to clarify this controversy. Additionally, highly potent and selective ML 
agonists, including tasimelteon, ramelteon, piromelatin and IK7 have been used in sleep 
disorders. However, there is no sufficient clinical support for the exact influence of 
these drugs on glucose homeostasis, insulin secretion and diabetes risk (43). More 
research exploring the effects of exogenous melatonin and its potential agonists on 
glucose metabolism is required. 
 
 
 
CLINICAL IMPLICATIONS 
 
Melatonin seems a potent additional treatment in glucose homeostasis, 
preventing from glucose intolerance, diabetes and associated comorbidities. These 
effects are especially due to its central capacity to reset central clock, while coordinating 
peripheral clock machinery. These effects are especially important when referring to 
people forced to timing disruption as exposure to light during night, shift work, social 
and jet lag, as other concerns in nowadays society, especially when other metabolic 
disturbances are involved.  Therefore, this clock dysfunction may contribute to the 
emerging worldwide prevalence of T2DM. A vicious circle between these conditions 
appears highly probable. Indeed, diabetes may lead to sleep disorders and consequently 
to rhythmic disturbances that can interfere with melatonin dysregulation patterns and 
exacerbate this process. Considering the importance of adequate timing of food intake, 
exercise, adequate sleep habits and exposure to light, we highly support patients under 
irregular schedules should be advised to improve or maintain metabolic health. Finally, 
it is important to clarify the putative role of melatonin in preventing diabetes in pre-
diabetic patients, mainly when circadian disruption factors are present, as in the 
protection from circadian disruption when diabetes is already established. One of the 
next steps could also be to evaluate rational combinations of melatonin or its agonists 
with other antidiabetic therapeutic agents.  
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Figure 1: During the night, Melatonin (ML) is released from pineal gland following a circadian rhythm controlled by the “master 
circadian clock” on suprachiasmatic nucleus (SCN). ML acts mainly through MT1 and MT2, two high-affinity G protein-coupled 
receptors. ML can also exerts its functions binding to a third ML receptor, previously defined as MT3, a member of the quinone 
reductases family, through  nuclear  receptors, called  retinoid-related orphan nuclear hormone receptor from RZR/RORα family 
and through direct interactions with intracellular proteins, including calmodulin, calreticulin and tubulin. ML influences circadian 
biologic rhythm and has important functions in other peripheral organs and cells. Simultaneously, other stimuli have impact on 
circadian clock, as epigenetic factors, social environment, food intake, exercise and biological stress. Natural, or artificial light, is 
detected by retinal photoreceptors and action potentials are transferred, via retinohypothalamic tract, to the SCN, situated in the 
ventral part of the hypothalamus, leading to ML synthesis suppression. 
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• Figure 2:  Factors such as shift work, “jet lag” due to travels across several time zones, “social jet lag” in a context of changes 
in sleep behavior, sleep disorders, exposition to nocturnal lighting, mainly due to electronic devices use, and caffeine and 
alcohol consume have been associated to chronodisruption and consequent impairment of melatonin secretion normal 
patterns. This imbalance leads to cardiovascular consequences as coronary disease, myocardial infarction and 
cerebrovascular accident, to increase the risk of some cancer types, particularly breast, colon and prostate, and to metabolic 
disorders, as glucose intolerance, insulin resistance, obesity, dyslipidemia and metabolic syndrome.  These last conditions 
might in turn be able to disturb the circadian clock in other organs and consequently to exacerbate metabolic disease.  
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• Figure 3: Disruption of circadian rhythm (chronodisruption) is implicated in diabetes pathogenesis.  Its mechanisms might be 
related with sleep disorders, alterations in clock gene expression and timing disruption of biologic functions and food intake. 
Leading to melatonin (ML) secretion impairments, disruption of circadian rhythm can also result in a decrease in insulin 
response, Glut4 expression and  hepatic and muscular glycogenesis, increase in blood pyruvate concentrations and food 
consumption, and glucose intolerance, contributing to diabetes development. Other circadian disruption consequences are  
responsible for obesity pathogenesis, a main risk factor for type 2 diabetes mellitus (T2DM), as decreased metabolic rate, 
weight gain, decreased brown adipose tissue (BAT)  activity, which has protective role in diabetes and in glucose 
homeostasis, hyperphagia, hyperlipidemia, hepatic steatosis and gut microbiome, adipocyte clock, molecules and hormones ( 
leptin and adiponectin) secretion dysregulation. Inversion of cortisol profile and a decrease in glucagon levels, both 
consequences of chronodisruption, influence negatively glucose homeostasis and consequently increase T2DM risk.  
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